Spoken and Unspoken Matters Regarding the Use of Opioids in Cancer

References

• Sullivan DR, Chan B, Lapidus JA, et al. Association of early palliative care use with survival and place of death among patients with advanced lung cancer receiving care in the Veterans Health Administration. JAMA Oncol. 2019;5(12):1702–1709. doi:10.1001/jamaoncol.2019.3105
   PubMed Web of Science ®Google Scholar
• Weiland G, Frisman D, Taylor P. Affinity labeling of the subunits of the membrane associated cholinergic receptor. Mol Pharmacol. 1979;15:213–226.
   PubMed Web of Science ®Google Scholar
• Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem. 1993;295(Pt3):625–628. doi:10.1042/bj2950625
   Web of Science ®Google Scholar
• Yasuda K, Raynor K, Kong H, et al. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci USA. 1993;90(14):6736–6740. doi:10.1073/pnas.90.14.6736
   PubMed Web of Science ®Google Scholar
• Vass M, Kooistra AJ, Yang D, Stevens RC, Wang MW, de Graaf C. Chemical diversity in the G protein-coupled receptor superfamily. Trends Pharmacol Sci. 2018;39(5):494–512. doi:10.1016/j.tips.2018.02.004
   PubMed Web of Science ®Google Scholar
• Mollereau C, Parmentier M, Mailleux P, et al. ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Lett. 1994;341(1):33–38. doi:10.1016/0014-5793(94)80235-1
   PubMed Web of Science ®Google Scholar
• Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res. 2000;856(1–2):75–83. doi:10.1016/S0006-8993(99)02330-6
   PubMed Web of Science ®Google Scholar
• Peng J, Sarkar S, Chang SL. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend. 2012;124(3):223–228. doi:10.1016/j.drugalcdep.2012.01.013
   PubMed Web of Science ®Google Scholar
• Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018;43(13):2514–2520. doi:10.1038/s41386-018-0225-3
   PubMed Web of Science ®Google Scholar
• Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004;73(1):953–990. doi:10.1146/annurev.biochem.73.011303.073940
   PubMed Web of Science ®Google Scholar
• Shang Y, Filizola M. Opioid receptors: structural and mechanistic insights into pharmacology and signaling. Eur J Pharmacol. 2015;763(Pt B):206–213. doi:10.1016/j.ejphar.2015.05.012
   PubMed Web of Science ®Google Scholar
• Gomes I, Sierra S, Lueptow L, et al. Biased signaling by endogenous opioid peptides. Proc Natl Acad Sci USA. 2020;117(21):11820–11828. doi:10.1073/pnas.2000712117
   PubMed Web of Science ®Google Scholar
• Toll L, Bruchas MR, Calo’ G, Cox BM, Zaveri NT. Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev. 2016;68(2):419–457. doi:10.1124/pr.114.009209
   PubMed Web of Science ®Google Scholar
• Manglik A. Molecular basis of opioid action: from structures to new leads. Biol Psych. 2020;87(1):6–14. doi:10.1016/j.biopsych.2019.08.028
   PubMed Web of Science ®Google Scholar
• Jang HS, Shin WJ, Lee JE, Do JT. CpG and non-CpG methylation in epigenetic gene regulation and brain function. Genes. 2017;8(6):2–20. doi:10.3390/genes8060148
   Web of Science ®Google Scholar
• Abrimian A, Kraft T, Pan Y-X. Endogenous opioid peptides and alternatively spliced mu opioid receptor seven transmembrane carboxyl-terminal variants. Int J Mol Sci. 2021;22(7):343. doi:10.3390/ijms22073779
   Web of Science ®Google Scholar
• Zhang T, Xu J, Pan Y-X. A truncated six transmembrane splice variant mor-1g enhances expression of the full-length seven transmembrane μ-opioid receptor through heterodimerization. Mol Pharmacol. 2020;8(4):518–527. doi:10.1124/mol.120.119453
   Web of Science ®Google Scholar
• Jullié D, Gondin AB, von Zastrow M, Canals M. Opioid pharmacology under the microscope. Mol Pharmacol. 2020;98(4):425–432. doi:10.1124/mol.119.119321
   PubMed Web of Science ®Google Scholar
• Lu Z, Xu J, Rossi GC, Majumdar S, Pasternak GW, Pan Y-X. Mediation of opioid analgesia by a truncated 6-transmembrane GPCR. J Clin Invest. 2015;125(7):2626–2630. doi:10.1172/JCI81070
   PubMed Web of Science ®Google Scholar
• Pasternak GW, Pan Y-X. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257–1317. doi:10.1124/pr.112.007138
   PubMed Web of Science ®Google Scholar
• Mace G, Miaczynska M, Zerial M, Nebreda AR. Phosphorylation of EEA1 by p38 MAP kinase regulates μ opioid receptor endocytosis. EMBO J. 2005;24(18):3235–3246. doi:10.1038/sj.emboj.7600799
   PubMed Web of Science ®Google Scholar
• Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by β-arrestins. Science. 2005;308(5721):512–517. doi:10.1126/science.1109237
   PubMed Web of Science ®Google Scholar
• Ferguson SS, Downey WEIII, Colapietro AM, Barak LS, Menard L, Caron MG. Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science. 1996;271(5247):363–366. doi:10.1126/science.271.5247.363
   PubMed Web of Science ®Google Scholar
• Celver J, Xu M, Jin W, Lowe J, Chavkin C. Distinct domains on the μ-opioid receptor control uncoupling and internalization. Mol Pharmacol. 2004;65(3):528–537. doi:10.1124/mol.65.3.528
   PubMed Web of Science ®Google Scholar
• Whistler JL. Functional dissociation of mu opioid receptor- signaling and endocytosis: implications for the biology of tolerance and addiction. Neuron. 1999;23(4):737–746. doi:10.1016/s0896-6273(01)80032-5
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001;24(2):97–129. doi:10.1016/S0893-133X(00)00195-0
   PubMed Web of Science ®Google Scholar
• Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev. 2001;81(1):299–343. doi:10.1152/physrev.2001.81.1.299
   PubMed Web of Science ®Google Scholar
• Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA. 1998;95(17):9914–9919. doi:10.1073/pnas.95.17.9914
   PubMed Web of Science ®Google Scholar
• Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 1995;82(5):1226–1236. doi:10.1097/00000542-199505000-00018
   PubMed Web of Science ®Google Scholar
• Yuan L, Luo L, Ma X, et al. Chronic morphine induces cyclic adenosine monophosphate formation and hyperpolarization-activated cyclic nucleotide-gated channel expression in the spinal cord of mice. Neuropharmacology. 2020;176:108222. doi:10.1016/j.neuropharm.2020.108222
   PubMed Web of Science ®Google Scholar
• Bonci A, Williams JT. Increased probability of GABA release during withdrawal from morphine. J Neurosci. 1997;17(2):796–803. doi:10.1523/JNEUROSCI.17-02-00796.1997
   PubMed Web of Science ®Google Scholar
• Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron. 2001;32(5):829–839. doi:10.1016/s0896-6273(01)00517-7
   PubMed Web of Science ®Google Scholar
• Koob GF, Simon EF. The neurobiology of addiction: where we have been and where we are going. J Drug Issues. 2009;39(1):115–132. doi:10.1177/002204260903900110
   PubMed Web of Science ®Google Scholar
• Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14(5):381–395. doi:10.1016/S0898-6568(01)00271-6
   PubMed Web of Science ®Google Scholar
• Sun Y, Liu W-Z, Liu T, Feng X, Yang N, Zhou H-F. Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct. 2015;35(6):600–604. doi:10.3109/10799893.2015.1030412
   PubMed Web of Science ®Google Scholar
• Biki B, Mascha E, Moriarty DC, Fitzpatrick JM, Sessler DI, Buggy DJ. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology. 2008;109(2):180–187. doi:10.1097/ALN.0b013e31817f5b73
   PubMed Web of Science ®Google Scholar
• Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105(4):660–664. doi:10.1037/a0030561
   PubMed Web of Science ®Google Scholar
• Christopherson R, James KE, Tableman M, Marshall P, Johnson FE. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg. 2008;107(1):325–332. doi:10.1213/ane.0b013e3181770f55
   PubMed Web of Science ®Google Scholar
• Schlagenhauff B, Ellwanger U, Breuninger H, Stroebel W, Rassner G, Garbe C. Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res. 2000;10(2):165–169. doi:10.1097/00008390-200004000-00009
   PubMed Web of Science ®Google Scholar
• Mathew B, Lennon FE, Siegler JH, et al. Novel role of the mu opioid receptor in lung cancer progression: a laboratory study. Anesth Analg. 2011;112(3):558–567. doi:10.1213/ANE.0b013e31820568af
   PubMed Web of Science ®Google Scholar
• Zylla D, Kuskowski MA, Gupta K, Gupta P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014;113(suppl 1):i109–116. doi:10.1093/bja/aeu351
   PubMedGoogle Scholar
• Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg. 2011;113(6):1353–1364. doi:10.1213/ANE.0b013e318232b35a
   PubMed Web of Science ®Google Scholar
• Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res. 2006;3(3):171–180. doi:10.2174/156720206778018767
   PubMed Web of Science ®Google Scholar
• Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62(15):4491–4498.
   PubMed Web of Science ®Google Scholar
• Singleton PA, Lingen M, Fekete M, Garcia J, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res. 2006;72(1–2):3–11. doi:10.1016/j.mvr.2006.04.004
   PubMed Web of Science ®Google Scholar
• Wei Y, Zhang B, Li X, et al. Upregulation and activation of δ–opioid receptors promote the progression of human breast cancer. Oncol Rep. 2016;36(5):2579–2586. doi:10.3892/or.2016.5109
   PubMed Web of Science ®Google Scholar
• Oskoueian E, Abdullah N, Ahmad S. Phorbol esters from Jatropha meal triggered apoptosis, activated PKC‑δ, caspase‑3 proteins and down‑regulated the proto‑oncogenes in MCF-7 and HeLa cancer cell lines. Molecules. 2012;17(9):10816–10830. doi:10.3390/molecules170910816
   PubMed Web of Science ®Google Scholar
• Zhu M, Li M, Yang F, et al. Mitochondrial ERK plays a key role in δ‑opioid receptor neuroprotection against acute mitochondrial dysfunction. Neurochem Int. 2011;59(6):739‑748. doi:10.1016/j.neuint.2011.08.005
   Web of Science ®Google Scholar
• Sancho P, Galeano E, Estañ MC, Ganan‑Gomez I, Boyano‑Adanez MC, Garcia‑Perez AI. Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562. Exp Biol Med. 2012;237(8):933–942. doi:10.1258/ebm.2012.011423
   Web of Science ®Google Scholar
• Tripolt S, Neubauer HA, Knab VM, et al. Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3. Neoplasia. 2021;23(2):270–279. doi:10.1016/j.neo.2020.12.011
   PubMed Web of Science ®Google Scholar
• Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelial-mesenchymal transitions in carcinomas. JAK-STAT. 2014;3(1):e28975. doi:10.4161/jkst.28975
   PubMedGoogle Scholar
• Friesen C, Roscher M, Alt A, Miltner E. Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance. Cancer Res. 2008;68(15):6059–6064. doi:10.1158/0008-5472.CAN-08-1227
   PubMed Web of Science ®Google Scholar
• Friesen C, Hormann I, Roscher M, et al. Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle. 2014;13(10):1560–1570. doi:10.4161/cc.28493
   PubMed Web of Science ®Google Scholar
• He G, Li LI, Guan E, Chen J, Qin YI, Xie Y. Fentanyl inhibits the progression of human gastric carcinoma MGC-803 cells by modulating NF-kappaB-dependent gene expression in vivo. Onc Lett. 2016;12(1):563–571. doi:10.3892/ol.2016.4619
   PubMed Web of Science ®Google Scholar
• Decker D, Schöndorf M, Bidlingmaier F, et al. Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to trauma. Surgery. 1996;119(3):316–325. doi:10.1016/s0039-6060(96)80118-8
   PubMed Web of Science ®Google Scholar
• Kutza J, Gratz I, Afshar M, et al. The effects of general anesthesia and surgery on basal and interferon stimulated natural killer cell activity of humans. Anesth Analg. 1997;85(4):918–923. doi:10.1097/00000539-199710000-00037
   PubMed Web of Science ®Google Scholar
• Riboli EB, Terrizzi A, Arnulfo G, et al. Immunosuppressive effect of surgery evaluated by the multitest cell-mediated immunity system. Can J Surg. 1984;27(1):60–63.
   PubMed Web of Science ®Google Scholar
• Filipczak-Bryniarska I, Nowak B, Sikora E, et al. The influence of opioids on the humoral and cell-mediated immune responses in mice. The role of macrophages. Pharmacol Rep. 2012;64(5):1200–1215. doi:10.1016/S1734-1140(12)70916-7
   PubMed Web of Science ®Google Scholar
• Garcia JB, Cardoso MG, Dos-Santos MC. Opioids and the immune system: clinical relevance. Rev Bras Anesthesiol. 2012;62(5):709–718. doi:10.1016/S0034-7094(12)70169-1
   PubMed Web of Science ®Google Scholar
• Nørregaard R, Kwon TH, Frøkiær J. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney. Kidney Res Clin Pract. 2015;34(4):194–200. doi:10.1016/j.krcp.2015.10.004
   PubMed Web of Science ®Google Scholar
• Lee KY, Kim YJ, Yoo H, Lee SH, Park JB, Kim HJ. Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood-brain barrier. Anticancer Res. 2011;31(12):4307–4313.
   PubMed Web of Science ®Google Scholar
• Ross G, Gabra B, Dewey W, Akbarali H. Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther. 2008;327(2):561–572. doi:10.1124/jpet.108.143438
   PubMed Web of Science ®Google Scholar
• Nelson AD, Camilleri M. Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015;8(4):206–220. doi:10.1177/1756283X15578608
   PubMed Web of Science ®Google Scholar
• Galligan J, Akbarali H. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014;2(1):17–21.
   PubMedGoogle Scholar
• Kang M, Maguma HT, Smith TH, Ross GR, Dewey WL, Akbarali HI. The role of β-arrestin2 in the mechanism of morphine tolerance in the mouse and Guinea pig gastrointestinal tract. J Pharmacol Exp Ther. 2012;340(3):567–576. doi:10.1124/jpet.111.186320
   PubMed Web of Science ®Google Scholar
• Claing A, Laporte SA, Caron MG, et al. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol. 2002;66(2):61–79. doi:10.1016/s0301-0082(01)00023-5
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Portoghese PS, Takamori AE. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther. 1991;257(2):676–680.
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Portoghese PS, Takemori AE. Involvement of delta 2 opioid receptors in the development of morphine dependence in mice. J Pharmacol Exp Ther. 1993;264(3):1141–1145.
   PubMed Web of Science ®Google Scholar
• Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J. 2006;8(1):E118–125. doi:10.1208/aapsj080114
   PubMed Web of Science ®Google Scholar
• North RA, Williams JT, Surprenant A, et al. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci USA. 1987;84(15):5487–5491. doi:10.1073/pnas.84.15.5487
   PubMed Web of Science ®Google Scholar
• Surprenant A, Shen KZ, North RA, et al. Inhibition of calcium currents by noradrenaline, somatostatin and opioids in Guinea-pig submucosal neurones. J Physiol. 1990;431:585–608. doi:10.1113/jphysiol.1990.sp018349
   PubMed Web of Science ®Google Scholar
• Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363–371. doi:10.1056/NEJMra1511480
   PubMed Web of Science ®Google Scholar
• Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res. 1998;8(12):1229–1231. doi:10.1101/gr.8.12.1229
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse. 2002;46(2):79–82. doi:10.1002/syn.10137
   PubMed Web of Science ®Google Scholar
• Hou QF, Li SB. Potential association of DRD2 and DAT1 genetic variation with heroin dependence. Neurosci Lett. 2009;464(2):127–130. doi:10.1016/j.neulet.2009.08.004
   PubMed Web of Science ®Google Scholar
• Lawford BR, Young RM, Noble EP, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet. 2000;96(5):592–598. doi:10.1002/1096-8628(20001009)96:5<592:aid-ajmg3>3.0.co;2-y
   PubMed Web of Science ®Google Scholar
• Kapur S, Sharad S, Singh RA, Gupta AK. A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J Integr Neurosci. 2007;6(4):511–522. doi:10.1142/s0219635207001635
   PubMedGoogle Scholar
• Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA. 1998;95(16):9608–9613. doi:10.1073/pnas.95.16.9608
   PubMed Web of Science ®Google Scholar
• Deng N, Zhou H, Fan H, Yuan Y. Single nucleotide polymorphisms and cancer susceptibility. Oncotarget. 2017;8(66):110635–110649. doi:10.18632/oncotarget.22372
   PubMedGoogle Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71. doi:10.1126/science.7545954
   PubMed Web of Science ®Google Scholar
• Huen MSY, Sy SMH, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 2010;11(2):138–148. doi:10.1038/nrm2831
   PubMed Web of Science ®Google Scholar
• Nicoloso MS, Sun H, Spizzo R, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res. 2010;70(7):2789–2798. doi:10.1158/0008-5472.CAN-09-3541
   PubMed Web of Science ®Google Scholar
• Wang K, Xu L, Pan L, Xu K, Li G. The functional BRCA1 rs799917 genetic polymorphism is associated with gastric cancer risk in a Chinese Han population. Tumour Biol. 2015;36(1):393–397. doi:10.1007/s13277-014-2655-9
   PubMedGoogle Scholar
• Zhang X, Wei J, Zhou L, et al. Functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma. Carcinogenesis. 2013;34(10):2309–2313. doi:10.1093/carcin/bgt213
   PubMed Web of Science ®Google Scholar
• Liu D, Gao Y, Li L, et al. Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer. Oncol Lett. 2021;21(5):424. doi:10.3892/ol.2021.12685
   PubMed Web of Science ®Google Scholar
• Kendler KS, Prescott CA, Myers J, Neale MC. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry. 2003;60(9):929–937. doi:10.1001/archpsyc.60.9.929
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726–734. doi:10.1038/nrc3130
   PubMed Web of Science ®Google Scholar
• Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153(1):38–55. doi:10.1016/j.cell.2013.03.008
   PubMed Web of Science ®Google Scholar
• Maze I, Nestler EJ. The epigenetic landscape of addiction. Ann NY Acad Sci. 2011;1216:99–113. doi:10.1111/j.1749-6632.2010.05893.x
   PubMed Web of Science ®Google Scholar
• Hwang CK, Song KY, Kim CS, et al. Evidence of endogenous mu opioid receptor regulation by epigenetic control of the promoters. Mol Cell Biol. 2007;27(13):4720–4736. doi:10.1128/MCB.00073-07
   PubMed Web of Science ®Google Scholar
• Nielsen DA, Yuferov V, Hamon S, et al. Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. Neuropsychopharmacology. 2009;34(4):867–873. doi:10.1038/npp.2008
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Lombaerts M, van Wezel T, Philippo K, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer. 2006;94(5):661–671. doi:10.1038/sj.bjc.6602996
   PubMed Web of Science ®Google Scholar
• Pfeifer GP, Yoon J-H, Liu L, Tommasi S, Wilczynski SP, Dammann R. Methylation of the RASSF1A gene in human cancers. Biol Chem. 2002;383(6):907–914. doi:10.1515/BC.2002.097
   PubMed Web of Science ®Google Scholar
• Kanai Y, Ushijima S, Nakanishi Y, Sakamoto M, Hirohashi S. Mutation of the DNA methyltransferase (DNMT) 1 gene in human colorectal cancers. Cancer Lett. 2003;192(1):75–82. doi:10.1016/s0304-3835(02)00689-4
   PubMed Web of Science ®Google Scholar
• Nakayama T, Kaneko M, Kodama M, Nagata C. Cigarette smoke induces DNA single-strand breaks in human cells. Nature. 1985;314(6010):462–464. doi:10.1038/314462a0
   PubMed Web of Science ®Google Scholar
• Ishida M, Ishida T, Tashiro S, et al. Smoking cessation reverses DNA double-strand breaks in human mononuclear cells. PLoS One. 2014;9(8):e103993. doi:10.1371/journal.pone.0103993
   PubMed Web of Science ®Google Scholar
• Toller IM, Neelsen KJ, Steger M, et al. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. PNAS. 2011;108(36):14944–14949. doi:10.1073/pnas.1100959108
   PubMed Web of Science ®Google Scholar
• Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulvedaal AR. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology. 2002;123(2):542–553. doi:10.1053/gast.2002.34751
   PubMed Web of Science ®Google Scholar
• Soria J-C, Mok TS, Cappuzzo F, Jänne PA. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev. 2012;38(5):416–430. doi:10.1016/j.ctrv.2011.10.003
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. doi:10.1056/NEJMoa022457
   PubMed Web of Science ®Google Scholar
• Carey LA. HER2-a good addiction. Nat Rev Clin Oncol. 2012;9(4):196–197. doi:10.1038/nrclinonc.2012.36
   PubMed Web of Science ®Google Scholar
• Ahn M-J, Tsai C-M, Shepherd FA, et al. Osimertinib in patients with T790M mutation-positive, advanced non–small cell lung cancer: long-term follow-up from a pooled analysis of 2 Phase 2 studies. Cancer. 2019;125(6):892–901. doi:10.1002/cncr.31891
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743. doi:10.1056/NEJMoa064320
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68(9):3077–3080. doi:10.1158/0008-5472.CAN-07-3293
   PubMed Web of Science ®Google Scholar
• Rajan SS, Amin AD, Li L, et al. The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. Oncogene. 2020;39(10):2103–2117. doi:10.1038/s41388-019-1136-4
   PubMed Web of Science ®Google Scholar